The Priority Review

Tag

GlaxoSmithKline

1 story

  1. Clinical trials

    GlaxoSmithKline registers phase 3 trial of mRNA seasonal influenza vaccine

    This study was first posted on ClinicalTrials.gov on October 1, 2026. The trial plans to enroll 3000 participants and aims to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine in adults 18-64 years of age.